| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Cdc7-IN-7c targets cell division cycle 7 (Cdc7) kinase, a serine/threonine kinase that is essential for the initiation of DNA replication. It is a time-dependent inhibitor with slow dissociation kinetics, allowing for sustained target engagement. The compound shows high selectivity for Cdc7 over other kinases, including CDK2 (>14,000-fold) and ROCK1 (200-fold).
|
|---|---|
| ln Vitro |
Cdc7-IN-7c is a highly potent and selective Cdc7 kinase inhibitor with an IC50 of 0.70 nM. It demonstrates time-dependent inhibition with slow dissociation properties. The compound shows >14,000-fold selectivity over CDK2 and 200-fold selectivity over ROCK1. It has demonstrated cellular pharmacodynamic effects in the COLO205 colorectal cancer model.
|
| ln Vivo |
Specific in vivo activity data for Cdc7-IN-7c is not extensively detailed in the available literature. It has demonstrated cellular pharmacodynamic effects in the COLO205 colorectal cancer model. As a potent Cdc7 inhibitor, it has antitumor activity and inhibitory effects on various cancers, including liver, lung, kidney, brain, and cervical cancer. Further in vivo studies are needed to fully characterize its efficacy.
|
| Enzyme Assay |
Cdc7-IN-7c's activity as a Cdc7 kinase inhibitor is assessed using in vitro kinase assays. These assays measure the compound's ability to inhibit the phosphorylation activity of Cdc7 kinase. The IC50 value of 0.70 nM is determined from dose-response curves. Selectivity profiling against a panel of other kinases is performed to confirm its specificity.
|
| Cell Assay |
Cellular assays for Cdc7-IN-7c involve treating cancer cell lines with the compound and measuring its effects on cell proliferation and viability. The compound's ability to inhibit Cdc7-mediated phosphorylation of its substrates in cells can be assessed by Western blot analysis. Cellular pharmacodynamic effects have been demonstrated in the COLO205 colorectal cancer model.
|
| Animal Protocol |
In vivo animal model protocols for Cdc7-IN-7c would involve its administration to tumor-bearing mice to evaluate its antitumor efficacy. Studies may include models of liver, lung, kidney, brain, and cervical cancer. Tumor growth inhibition, pharmacodynamic markers, and pharmacokinetic parameters would be assessed.
|
| ADME/Pharmacokinetics |
Cdc7-IN-7c has a molecular weight of 315.39 and a molecular formula of C15H17N5OS. It is soluble in DMSO and is supplied as a solid powder. Specific pharmacokinetic data is not extensively detailed in the available literature. The compound's time-dependent inhibition and slow dissociation kinetics suggest prolonged target engagement.
|
| Toxicity/Toxicokinetics |
Cdc7-IN-7c is intended for research use only and not for human consumption. As a research compound, its comprehensive toxicological profile may not be fully characterized. Standard safety assessments would be required for clinical development. The compound is typically stored in dry, dark conditions at -20°C for long-term stability.
|
| References | |
| Additional Infomation |
Cdc7-IN-7c (CAS# 1330781-04-8) is a research compound used to study the role of Cdc7 kinase in DNA replication and cancer. It is a highly potent, selective, and time-dependent Cdc7 inhibitor with sub-nanomolar potency and excellent selectivity. It is not approved for clinical use and is supplied as a solid powder for research purposes.
|
| Molecular Formula |
C15H17N5OS
|
|---|---|
| Molecular Weight |
315.39
|
| Exact Mass |
315.115
|
| CAS # |
1330781-04-8
|
| PubChem CID |
136333907
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.805
|
| LogP |
1.71
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
479
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C(C2C=NNC=2C)=CC2=C1C(NC(CN1CCCC1)=N2)=O
|
| InChi Key |
MUYIKPWUBQUQAV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H17N5OS/c1-9-10(7-16-19-9)12-6-11-14(22-12)15(21)18-13(17-11)8-20-4-2-3-5-20/h6-7H,2-5,8H2,1H3,(H,16,19)(H,17,18,21)
|
| Chemical Name |
6-(5-methyl-1H-pyrazol-4-yl)-2-(pyrrolidin-1-ylmethyl)-3H-thieno[3,2-d]pyrimidin-4-one
|
| Synonyms |
Cdc7IN7c; Cdc7 IN 7c; Cdc7-IN-7c
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1707 mL | 15.8534 mL | 31.7068 mL | |
| 5 mM | 0.6341 mL | 3.1707 mL | 6.3414 mL | |
| 10 mM | 0.3171 mL | 1.5853 mL | 3.1707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
